METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for drug-resistant prostate cancer: targeted radiation vs. standard therapy
Disease control OngoingThis study tests a radioactive drug (Lu-PSMA-617) against a switch to another hormone therapy in Chinese men with advanced prostate cancer that has spread and stopped responding to treatment. The goal is to see if the radioactive drug can delay cancer growth better than changing …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 06:07 UTC
-
New hope for advanced cancers: experimental drug NUV-1511 enters human trials
Disease control OngoingThis study tests a new drug called NUV-1511 in adults with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors. The study includes people with certain breast, prostate, pancreatic, and ovarian can…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated May 26, 2026 05:50 UTC
-
New radiation therapy shows promise for Tough-to-Treat prostate cancer
Disease control OngoingThis study is testing a new treatment called 177Lu-PSMA-617 for Chinese men with a type of advanced prostate cancer that has spread and is no longer responding to hormone therapy or chemotherapy. The treatment delivers radiation directly to cancer cells, aiming to shrink tumors a…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New combo therapy aims to control advanced prostate cancer
Disease control OngoingThis study is for men with a type of advanced prostate cancer that has stopped responding to hormone therapy. It tests whether adding a radioactive drug (lutetium-177 vipivotide tetraxetan) to another hormone therapy is safe and works better than the radioactive drug alone. The g…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
Cancer patients monitored for long-term side effects in safety study
Knowledge-focused ENROLLING_BY_INVITATIONThis study enrolls 120 people with different cancers who already received treatment in an earlier study. The goal is to track serious side effects and other health issues over time. No new treatment is given; participants are simply monitored for safety.
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Knowledge-focused
Last updated May 26, 2026 06:05 UTC